Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Olaparib Monotherapy vs Combination Therapy for Breast Cancer
Recruiting1 awardPhase 2
Kettering, Ohio
This trial is testing two different treatments for triple negative breast cancer patients who have not responded to earlier treatments. One treatment is olaparib monotherapy and the other is olaparib in combination with an inhibitor of ATR. The study will enroll approximately 300 patients who will be randomly assigned to one of the two treatment arms.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.